Novo Nordisk unveils promising PhIII data for hemophilia A treatment; Diabetics are paying twice as much for meds;

@FiercePharma: Top-read on FP Tuesday: Shaky Dendreon loses its CEO as debt payments loom. Article | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes.  More | Follow @TracyStaton

@EricPFierce: ICYMI from FiercePharmaManufacturing: New #FDA warning letter says Alabama compounder is making sterile drugs in unsanitary facility. Story | Follow @EricPFierce

@CarlyHFierce: Do reps push drugs off-label? Yes, a study suggests. Does it work? Also yes. FiercePharmaMarketing story | Follow @CarlyHFierce

@JustinHFierce: FDA voting today, tomorrow on opioid-induced constipation drug class, meds like Movantik could spell boom. More | Follow @JustinHFierce

> Novo Nordisk ($NVO) unveiled new Phase III data from a trial for its NovoEight recombinant coagulation factor that shows long-term reduction from bleeding in people with hemophilia A. Release

> Diabetics are paying about twice as much for treatment than they did a decade ago, according to Yale University researchers. Story

> Leading U.K. doctors and academics are warning the country's National Institute for Health and Care Excellence (NICE) against prescribing cholesterol-lowering statins. Article

> The U.S. federal government is divided over the use of prescription opioids for pain relief. More

> AbbVie ($ABBV) revealed results from a large global study that show that patients with more "accepting" attitudes toward their TNF inhibitors are more likely to adhere to treatment. Release

> Sanofi ($SNY) will present new clinical data about its diabetes products at the upcoming American Diabetes Association (ADA) 74th Scientific Sessions in San Francisco. Release

> Ten-year Novartis ($NVS) veteran Fabian Kausche has been appointed to lead global R&D at Sanofi's ($SNY) animal health division Merial. Release

Medical Device News

@FierceMedDev: Interesting: @Roche division @ventanamed helped shape a Dx masters degree program at @ArizonaState. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Bid for Allergan puts Valeant's research and development cuts under scrutiny. More from the WSJ (sub. req.) | Follow @VarunSaxena2

@StacyALawrence: ICYMI yesterday: FDA panel to consider first drug-eluting balloon catheter. Story | Follow @StacyALawrence

@MichaelGFierce: Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Women who are pregnant or breastfeeding should eat at least 8 oz of fish a week, according to new #FDA guidelines. More from the NYT | Follow @EmilyWFierce

> FDA releases details of Apple device meeting in response to FOIA request. More

> FDA approves Auxogyn embryo test for IVF procedures. Article

> Study demystifies U.S. diagnostic test costs. Story

Biotech News

@FierceBiotech: Can Orexigen and its partner Takeda escape the weight-drug jinx? Yesterday's analysis | Follow @FierceBiotech

@JohnCFierce: Lilly's key franchise drug ramucirumab flops in PhIII liver cancer study. More | Follow @JohnCFierce

@DamianFierce: Crushing realization that @Forbes' "What To Wear at BIO" feature applies solely to women. More | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday: Today's edition of Research is out. Newsletter | Follow @EmilyMFierce

> Billionaire Thiel backs biotech startups with eyes on Alzheimer's, GI disease. Report

> Old Roche R&D campus in NJ faces the wrecking ball. Item

> Hostile Allergan bid is part of Valeant's war on 'value-destroying' R&D. Story

> Rebel AstraZeneca investors push plan to tie exec pay to rosy R&D projections. Article

Pharma Marketing News

> Orexigen's weight-loss med sets up Takeda vs. Eisai marketing showdown--eventually. Article

> Feds cry foul at Allergan's free-speech defense in drug marketing case. Report

> New data backs GlaxoSmithKline's Incruse as an add-on to COPD med Breo Ellipta. Story

> Forest gives old Namenda a reprieve as switching to XR formula continues. More

> Men's Health Week or Low-T Week? Critics say awareness campaign is another pharma ploy. Article

Drug Delivery News

> UCSB study: New silver nanoparticles dissolve if they don't hit their mark. Article

> Avanir's nasal delivery for migraines beats oral sumatriptan in PhIIIb. Item

> Stem cells trapped in hydrogel better at bone repair. Story

> Cook launches Zilver PTX Drug-Eluting Stent in Canada. More

> Tonix receives IND approval for sublingual formulation to treat PTSD. Story

> Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. Article

Diagnostics News

> ImaginAb, Duke double down in Singapore on in vivo molecular imaging-agent work. More

> Roche's Ventana helped shape ASU's new Dx master's degree program. Story

> B. Braun will sell German partner's molecular Dx panels in the U.S. More

> China's FDA grants approval to Dehaier's portable sleep Dx system. Article

> AstraZeneca will tap Cancer Genetics' cancer biomarker testing tech in Central America. News

> Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test. Item

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.